An announcement from Adverum Biotechnologies (ADVM) is now available.
Adverum Biotechnologies recently shared updates on its LUNA Phase 2 trial of Ixoberogene soroparvovec (Ixo-vec) for treating wet age-related macular degeneration (AMD), showing promising interim results. The trial demonstrated that Ixo-vec significantly reduced the need for anti-VEGF injections, a common treatment for AMD, and maintained visual acuity and fluid control without serious adverse effects. A high percentage of patients preferred the Ixo-vec treatment over previous therapies, indicating its potential as a preferred AMD treatment. The company is preparing for further regulatory interactions and aims to initiate a Phase 3 trial in the first half of 2025.
See more insights into ADVM stock on TipRanks’ Stock Analysis page.
